Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer

被引：2
|
作者：
Nauseef, Jones T.
Sun, Michael
Thomas, Charlene
Bissassar, Mahelia
Fernandez, Escarleth
Davidson, Zachary
Patel, Amie
Tan, Angela
Chamberlain, Tessa A.
Earle, Kara
Wunder, Rebecca
Guervil, Sabrina
Castellanos, Sandra H.
Stangl-Kremser, Judith
Gregos, Peter S.
Osborne, Joseph R.
Ballman, Karla V.
Molina, Ana M.
Sternberg, Cora N.
Nanus, David M.
Bander, Neil H.
Tagawa, Scott T.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT014
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Fractionated carboplatin radiosensitization - A phase I dose-escalation study
    Koukourakis, MI
    Stefanaki, I
    Giatromanolaki, A
    Frangiadaki, C
    Armenaki, A
    Georgoulias, V
    Koumandakis, E
    Kranidis, A
    Helidonis, E
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (06): : 595 - 601
  • [22] Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
    Rathkopf, Dana
    Liu, Glenn
    Carducci, Michael A.
    Eisenberger, Mario A.
    Anand, Aseem
    Morris, Michael J.
    Slovin, Susan F.
    Sasaki, Yasutsuna
    Takahashi, Shunji
    Ozono, Seiichiro
    Fung, Nga Kit Eliza
    Cheng, Shinta
    Gan, Jinping
    Gottardis, Marco
    Obermeier, Mary T.
    Reddy, Jyotsna
    Zhang, Steven
    Vakkalagadda, Blisse J.
    Alland, Leila
    Wilding, George
    Scher, Howard I.
    CLINICAL CANCER RESEARCH, 2011, 17 (04) : 880 - 887
  • [23] Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer
    Mukai, Hirofumi
    Takahashi, Shunji
    Nozawa, Masahiro
    Onozawa, Yusuke
    Miyazaki, Jun
    Ohno, Keiji
    Suzuki, Kazuhiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 703 - 710
  • [24] Phase I Dose-escalation Study of (SBRT) for Localizes Prostate Cancer
    Ghaly, M.
    Marrero, M.
    Vijeh, L.
    Montchal, E.
    Lee, L.
    Potters, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S391 - S391
  • [25] Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer
    Hirofumi Mukai
    Shunji Takahashi
    Masahiro Nozawa
    Yusuke Onozawa
    Jun Miyazaki
    Keiji Ohno
    Kazuhiro Suzuki
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 703 - 710
  • [26] Baseline Imaging Derived Factors of Response Following [225Ac]Ac-J591 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Lesion Level Analysis
    Stangl-Kremser, Judith
    Ricaurte-Fajardo, Andres
    Huicochea Castellanos, Sandra
    Martinez-Fundichely, Alexander
    Sun, Michael
    Osborne, Joseph R.
    Nauseef, Jones T.
    Tagawa, Scott T.
    Bander, Neil H.
    PROSTATE, 2025, 85 (05): : 502 - 509
  • [27] Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer
    Nauseef, Jones T.
    Osborne, Joseph
    Gregos, Peter
    Thomas, Charlene
    Bissassar, Mahelia
    Singh, Sharon
    Patel, Amie
    Tan, Angela
    Naiz, Muhammad Obaid
    Zuloaga, Juana Martinez
    Chamberlain, Tessa
    Earle, Kara
    Wunder, Rebecca
    Nagar, Himanshu
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC)
    Vlachostergios, Panagiotis J.
    Goswami, Sukanya
    Niaz, Muhammad Junaid
    Thomas, Charlene
    Christos, Paul J.
    Osborne, Joseph
    Vallabhajosula, Shankar
    Molina, Ana M.
    Sternberg, Cora N.
    Singh, Sharon
    Tan, Angela
    Patel, Amie
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [29] Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC)
    Morris, Michael J.
    Pandit-Taskar, Neeta
    Carrasquillo, Jorge A.
    O'Donoghue, Joseph A.
    Humm, John
    Lyashchenko, Serge K.
    Haupt, Eric C.
    Bander, Neil Harrison
    Tagawa, Scott T.
    Holland, Jason P.
    Smith-Jones, Peter M.
    Lewis, Jason Stuart
    Solomon, Stephen Barnett
    Scher, Howard I.
    Larson, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [30] Phase I trial of fractionated-dose 177Lutetium radiolabeled antiprostate-specific membrane antigen (PSMA) monoclonal antibody. J591 (177Lu-J591) for metastatic castration-resistant prostate cancer (CRPC)
    Tagawa, S. T.
    Akhtar, N. H.
    Nikolopoulou, A.
    Vallabhajosula, S.
    Osborne, J.
    Beltran, H.
    Kahn, R.
    Goldsmith, S. J.
    Nanus, D. M.
    Bander, N. H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S701 - S702
12345